Replies to post #5059 on Ariad Pharmaceuticals Inc fka ARIA

[iandy]

From Barclays:
>We expect significant focus on secondary endpoints of overall survival (OS) and cancer related symptoms and believe that clinician rated progression is likely more indicative of overall patient benefit on these metrics than that from centralized radiologists.<

Nice way to start the day!